Goldman Sachs Reinstates Buy on Insmed, Announces $188 Price Target

Benzinga · 2d ago
Goldman Sachs analyst Andrea Newkirk reinstates Insmed (NASDAQ:INSM) with a Buy and announces $188 price target.